布地奈德福莫特罗联合噻托溴铵治疗慢阻肺稳定期的疗效及对生活质量的影响

目的探讨对慢性阻塞性肺疾病(慢阻肺)稳定期患者使用布地奈德福莫特罗联合噻托溴铵治疗的临床效果。方法 86例慢阻肺稳定期患者,随机分为对照组及实验组,各43例。对照组采用布地奈德福莫特罗治疗,实验组采用布地奈德福莫特罗联合噻托溴铵治疗。对比两组患者的治疗效果及生活质量评分。结果实验组总有效率95.35%高于对照组的76.74%,差异具有统计学意义(P<0.05)。对照组患者的社会功能评分为(13.62±1.68)分,情绪功能评分为(14.10±1.86)分,认知功能评分为(14.90±1.52)分,角色功能评分为(15.82±1.15)分,躯体功能评分为(15.65±1.47)分;实验组患者的社会功能评分为(18.22±1.71)分,情绪功能评分为(17.97±1.79)分,认知功能评分为(18.32±1.15)分,角色功能评分为(18.18±1.24)分,躯体功能评分为(18.78±1.42)分。实验组患者的生活质量评分均高于对照组,差异均具有统计学意义(P<0.05)。结论对慢阻肺稳定期患者采用布地奈德福莫特罗联合噻托溴铵用药方案进行治疗效果理想,且能够显著提高患者的生活质量,值得推广。

Efficacy of budesonide formoterol combined with tiotropium bromide on the stable chronic obstructive pulmonary disease and its influence on the quality of life

Objective To discuss the clinical effect of budesonide formoterol combined with tiotropium bromide on patients with stable chronic obstructive pulmonary disease. Methods A total of 86 patients with stable chronic obstructive pulmonary disease were randomly divided into control group and experimental group, with 43 cases in each group. The control group was treated by budesonide formoterol, and the experimental group was treated by budesonide formoterol combined with tiotropium bromide. The therapeutic effect and quality of life score was compared between the two groups. Results The total effective rate 95.35% in the experimental group was higher than 76.74% in the control group, and the difference was statistically significant(P<0.05). The social function score, emotional function score, cognitive function score, role function score and somatic function score were(13.62±1.68),(14.10±1.86),(14.90±1.52),(15.82±1.15) and(15.65±1.47) points respectively, which was(18.22±1.71),(17.97±1.79),(18.32±1.15),(18.18±1.24) and(18.78±1.42) points in the experimental group. The quality of life score in the experimental group was higher than those in the control group, and the difference was statistically significant(P<0.05). Conclusion Budesonide formoterol combined with tiotropium bromide shows ideal therapeutic effect on patients with stable chronic obstructive pulmonary disease, and it can significantly improve their quality of life. It is worthy of promotion.